{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T08:42:33Z","timestamp":1761986553357,"version":"3.44.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,30]],"date-time":"2021-04-30T00:00:00Z","timestamp":1619740800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.leukres.2021.106606","type":"journal-article","created":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T02:26:14Z","timestamp":1619835974000},"page":"106606","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Psychometric evaluation of the Advanced Systemic Mastocytosis Symptom Assessment Form (AdvSM-SAF)"],"prefix":"10.1016","volume":"108","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6474-4314","authenticated-orcid":false,"given":"Fiona","family":"Taylor","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoran","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Yip","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brad","family":"Padilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brenton","family":"Mar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanya","family":"Green","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronny","family":"Oren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony L.","family":"Boral","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui-Min","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3362-3135","authenticated-orcid":false,"given":"Alan L.","family":"Shields","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Gotlib","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.leukres.2021.106606_bib0005","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1038\/modpathol.2015.72","article-title":"Detection of the KIT D816V mutation in peripheral blood of systemic mastocytosis: diagnostic implications","volume":"28","author":"Jara-Acevedo","year":"2015","journal-title":"Mod. Pathol."},{"issue":"4","key":"10.1016\/j.leukres.2021.106606_bib0010","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1182\/blood-2007-11-078097","article-title":"Mast cells and mastocytosis","volume":"112","author":"Metcalfe","year":"2008","journal-title":"Blood."},{"issue":"4","key":"10.1016\/j.leukres.2021.106606_bib0015","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/bjh.12916","article-title":"Epidemiology of systemic mastocytosis in Denmark","volume":"166","author":"Cohen","year":"2014","journal-title":"Br. J. Haematol."},{"issue":"11","key":"10.1016\/j.leukres.2021.106606_bib0020","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1182\/blood-2016-09-731893","article-title":"Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts","volume":"129","author":"Valent","year":"2017","journal-title":"Blood."},{"issue":"2","key":"10.1016\/j.leukres.2021.106606_bib0025","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/ejh.12043","article-title":"Advanced systemic mastocytosis: the impact of KIT mutations in diagnosis, treatment, and progression","volume":"90","author":"Verstovsek","year":"2013","journal-title":"Eur. J. Haematol."},{"issue":"10069","key":"10.1016\/j.leukres.2021.106606_bib0030","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/S0140-6736(16)31403-9","article-title":"Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study","volume":"389","author":"Lortholary","year":"2017","journal-title":"Lancet."},{"issue":"26","key":"10.1016\/j.leukres.2021.106606_bib0035","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1056\/NEJMoa1513098","article-title":"Efficacy and safety of midostaurin in advanced systemic mastocytosis","volume":"374","author":"Gotlib","year":"2016","journal-title":"N. Engl. J. Med."},{"article-title":"Office of communications, division of drug information","year":"2009","author":"US Department of Health and Human Services","key":"10.1016\/j.leukres.2021.106606_bib0040"},{"issue":"8","key":"10.1016\/j.leukres.2021.106606_bib0045","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.jval.2011.06.014","article-title":"Content validity-establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 1-Eliciting concepts for a new PRO instrument","volume":"14","author":"Patrick","year":"2011","journal-title":"Value Health"},{"issue":"8","key":"10.1016\/j.leukres.2021.106606_bib0050","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1111\/j.1524-4733.2009.00603.x","article-title":"Use of existing patient-reported outcome (PRO) instruments and their modification: the ISPOR good research practices for evaluating and documenting content validity for the use of existing instruments and their modification PRO task force report","volume":"12","author":"Rothman","year":"2009","journal-title":"Value Health"},{"article-title":"Office of communications, division of drug information","year":"2019","author":"US Department of Health and Human Services","key":"10.1016\/j.leukres.2021.106606_bib0055"},{"issue":"8","key":"10.1016\/j.leukres.2021.106606_bib0060","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/j.jval.2011.06.013","article-title":"Content validity-establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 2-Assessing respondent understanding","volume":"14","author":"Patrick","year":"2011","journal-title":"Value Health"},{"key":"10.1016\/j.leukres.2021.106606_bib0065","series-title":"Paper Presented at: the 25th European Hematology Association Congress","article-title":"Avapritinib induces responses in patients with advanced systemic mastocytosis (AdvSM), regardless of prior midostaurin therapy","author":"Gotlib","year":"2020"},{"year":"2001","series-title":"The EORTC QLQ-C30 Scoring Manual","author":"Fayers","key":"10.1016\/j.leukres.2021.106606_bib0070"},{"issue":"5","key":"10.1016\/j.leukres.2021.106606_bib0075","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.leukres.2021.106606_bib0080","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12955-016-0427-5","article-title":"Interpreting change from patient reported outcome (PRO) endpoints: patient global ratings of concept versus patient global ratings of change, a case study among osteoporosis patients","volume":"14","author":"Nixon","year":"2016","journal-title":"Health Qual. Life Outcomes"},{"key":"10.1016\/j.leukres.2021.106606_bib0085","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the eastern cooperative oncology group","volume":"5","author":"Oken","year":"1982","journal-title":"Am. J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.leukres.2021.106606_bib0090","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1177\/0013164400602002","article-title":"Psychometrics is datametrics: the test is not reliable","volume":"60","author":"Thompson","year":"2000","journal-title":"Educ. Psychol. Meas."},{"issue":"7080","key":"10.1016\/j.leukres.2021.106606_bib0095","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1136\/bmj.314.7080.572","article-title":"Cronbach\u2019s alpha","volume":"314","author":"Bland","year":"1997","journal-title":"BMJ."},{"issue":"3","key":"10.1016\/j.leukres.2021.106606_bib0100","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/BF02310555","article-title":"Coefficient alpha and the internal structure of tests","volume":"16","author":"Cronbach","year":"1951","journal-title":"Psychometrika."},{"issue":"4","key":"10.1016\/j.leukres.2021.106606_bib0105","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1037\/1040-3590.6.4.284","article-title":"Guidelines, criteria, and rules of thumb for evaluating normed and standardized assessment instruments in psychology","volume":"6","author":"Cicchetti","year":"1994","journal-title":"Psychol. Assess."},{"issue":"2","key":"10.1016\/j.leukres.2021.106606_bib0110","first-page":"420","article-title":"Intraclass correlations: uses in assessing rater reliability","volume":"86","author":"Shrout","year":"1979","journal-title":"PsycholBull."},{"year":"1988","series-title":"Statistical Power Analysis for the Behavioral Sciences","author":"Cohen","key":"10.1016\/j.leukres.2021.106606_bib0115"},{"key":"10.1016\/j.leukres.2021.106606_bib0120","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1477-7525-3-23","article-title":"Assessing sensitivity to change: choosing the appropriate change coefficient","volume":"3","author":"Stratford","year":"2005","journal-title":"Health Qual. Life Outcomes"},{"year":"2013","series-title":"Patient-Reported Outcomes: Measurement, Implementation and Interpretation","author":"Cappelleri","key":"10.1016\/j.leukres.2021.106606_bib0125"},{"issue":"6","key":"10.1016\/j.leukres.2021.106606_bib0130","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1586\/14737167.2015.1115348","article-title":"Patient-reported outcomes for US oncology labeling: review and discussion of score interpretation and analysis methods","volume":"15","author":"Shields","year":"2015","journal-title":"Expert Rev. Pharmacoecon. Outcomes Res."},{"issue":"1","key":"10.1016\/j.leukres.2021.106606_bib0135","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1177\/2168479015622667","article-title":"Interpreting change in scores on patient-reported outcome instruments","volume":"50","author":"Coon","year":"2016","journal-title":"Ther. Innov. Regul. Sci."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212621001077?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212621001077?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:00:59Z","timestamp":1758934859000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212621001077"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":27,"alternative-id":["S0145212621001077"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2021.106606","relation":{},"ISSN":["0145-2126"],"issn-type":[{"type":"print","value":"0145-2126"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Psychometric evaluation of the Advanced Systemic Mastocytosis Symptom Assessment Form (AdvSM-SAF)","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2021.106606","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"106606"}}